U.S. markets open in 1 hour 57 minutes

  • S&P Futures

    4,483.00
    +7.50 (+0.17%)
     

  • Dow Futures

    35,330.00
    +49.00 (+0.14%)
     

  • Nasdaq Futures

    15,341.75
    +37.25 (+0.24%)
     

  • Russell 2000 Futures

    2,216.50
    +9.90 (+0.45%)
     

  • Crude Oil

    66.77
    +1.13 (+1.72%)
     

  • Gold

    1,807.50
    +1.20 (+0.07%)
     

  • Silver

    23.75
    +0.09 (+0.38%)
     

  • EUR/USD

    1.1743
    -0.0007 (-0.06%)
     

  • 10-Yr Bond

    1.2550
    0.0000 (0.00%)
     

  • Vix

    17.16
    -1.40 (-7.54%)
     

  • GBP/USD

    1.3713
    -0.0011 (-0.08%)
     

  • USD/JPY

    109.6770
    -0.0030 (-0.00%)
     

  • BTC-USD

    49,338.92
    -914.87 (-1.82%)
     

  • CMC Crypto 200

    1,249.69
    -13.76 (-1.09%)
     

  • FTSE 100

    7,094.69
    -14.33 (-0.20%)
     

  • Nikkei 225

    27,732.10
    +237.86 (+0.87%)
     

Global Companion Diagnostics Market Report 2021: Market to Reach $9.2 Billion by 2027 - U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 14.6% CAGR

Research and Markets
·3 min read

Dublin, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The "Companion Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Companion Diagnostics Market to Reach $9.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Companion Diagnostics estimated at US$3.4 Billion in the year 2020, is projected to reach a revised size of US$9.2 Billion by 2027, growing at a CAGR of 15.1% over the period 2020-2027.

Assay kits & Reagents, one of the segments analyzed in the report, is projected to record 14.3% CAGR and reach US$6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software & Services segment is readjusted to a revised 16.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 14.6% CAGR

The Companion Diagnostics market in the U.S. is estimated at US$1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 14.6% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.5% and 13% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • An Introductory Prelude

  • Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development

  • Broader Scope and Applications Rev Up Growth Opportunities

  • Healthy Growth Projected over the Next Few Years

  • Developed Regions: Key Revenue Contributors

  • Market Witnesses Fast Paced Growth in Developing Regions

  • Northbound Trajectory in R&D Spending Creates Conducive Environment

  • Prevailing Economic Scenario Favors Funding Pattern

2. FOCUS ON SELECT PLAYERS (Total 80 Featured)

  • Abbott Molecular

  • Agilent Technologies, Inc.

  • bioMerieux SA

  • Cepheid

  • Danaher Corporation

  • F. Hoffmann-La Roche Ltd.

  • Foundation Medicine Inc.

  • Laboratory Corporation of America Holdings

  • Leica Biosystems Nussloch GmbH

  • Merck & Co. Inc.

  • Myriad Genetics Inc.

  • NeoGenomics Laboratories, Inc.

  • QIAGEN N.V.

  • Quest Diagnostics Inc.

  • Thermo Fischer Scientific Inc.

3. MARKET TRENDS & DRIVERS

  • Growing Significance of Personalized Medicine Remains a Major Market Driver

  • Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum

  • Herceptin Lays the Road for Companion Diagnostics

  • Oncology - Dominant Therapy Area for CDx

  • Rising Incidence of Cancer Propels the Need for CDx Tests

  • Technology Advancements to Widen CDx Use Case

  • PCR: Dominant Technology Type for CDx Testing

  • Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing

  • Significant Role of Biomarkers in Companion Diagnostics

  • Critical Healthcare Needs of Aging Population Underpin CDx Sales

  • Regulatory Scenario Favors CDx Market

  • Resolving Prevailing Challenges: Critical for Future Growth of CDx Market

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 80

For more information about this report visit https://www.researchandmarkets.com/r/yn4tyo

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Recommended Stories

  • Why Canoo, Romeo Power, and Velodyne Lidar Are Surging Today

    One, Velodyne Lidar (NASDAQ: VLDR), was rising on new developments in an activist shareholder's battle with company management; Romeo Power (NYSE: RMO) and Canoo (NASDAQ: GOEV), by contrast, were up sharply on no apparent news -- but they (and Velodyne) may have been undergoing short squeezes. Canoo was up by about 26.7%. Romeo Power was up by about 16.1%.

  • 3 Big Dividend Stocks Yielding at Least 8%; RBC Says ‘Buy’

    Market trends are generally heading up, and investors are feeling confident. The S&P 500 has gained 20% so far this year, and the NASDAQ has gained 15%; for now, it looks like the confidence is justified. The economy’s reopening is proceeding apace, and both investors and consumers are looking forward to a more normal 2022. In a recent note for RBC, the firm’s head of US equity strategy, Lori Calvasina, acknowledges the optimism – and also points out the potential fly in the ointment. Stock perf

  • China Tech Stocks Rebound as Cathie Wood Joins Bargain Hunters

    (Bloomberg) -- Chinese technology stocks rallied for a second day as bargain hunters returned, emboldened by Tencent Holdings Ltd.’s share buyback and strong results from JD.com, which drew Cathie Wood back into the market.The Hang Seng Tech Index advanced more than 7%, adding to a 2% gain on Monday, after a five-week rout that took the gauge to the lowest level since its inception last year. Heavyweights Tencent and Alibaba Group Holding Ltd. climbed 8.8% and 9.5%, respectively.While there’s no

  • Cathie Wood is Doubling Down on These 10 Stocks

    In this article, we discuss the 10 stocks Cathie Wood is doubling down on. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood is Doubling Down on These 5 Stocks. Cathie Wood, the chief of New York-based ARK Investment Management, is a trail-blazing investor on Wall Street, who […]

  • Warren Buffett Is Selling These 10 Stocks

    In this article, we discuss the 10 stocks Warren Buffett is selling. If you want to skip our detailed analysis of these stocks, go directly to Warren Buffett Is Selling These 5 Stocks. Warren Buffett, the chief of Nebraska-based Berkshire Hathaway, is often referred to as the “Sage of Omaha” due to his incredibly successful […]

  • Chip shortage to worsen, Trillium pops 180% after Pfizer buyout, Coinbase reassures on stablecoins

    Yahoo Finance’s Jared Blikre reports on the day's trending tickers.

  • 2 Ultra-Yielding Dividend Giants Poised to Raise Dividends

    The Federal Reserve cut its benchmark rate to near zero to deal with COVID-19, and rates across the board have plummeted. Currently, the 30-year U.S. Treasury bond is yielding 1.93%, a figure even lower than during the financial crisis. At the same time, inflation is running above 5%, which means these investors are earning negative real returns and losing purchasing power!

  • AMD Is Stealing Market Share From Intel, and It's Not Stopping Now

    Intel's (NASDAQ: INTC) recovery in the x86 CPU (central processing unit) market at the end of 2020 now appears to be a flash in the pan. Intel had given investors hope that it could bring an end to Advanced Micro Devices' (NASDAQ: AMD) consistent market share gains by ramping up production and catering to customers who were unable to buy the latter's chips due to a supply shortage, but the latest numbers from Mercury Research prove otherwise. AMD ate into Intel's x86 market share in the second quarter of 2021, with its share now close to all-time highs.

  • Move Over, Tesla: There's a New Most-Held Stock on Robinhood

    Electric vehicle manufacturer Tesla has been dethroned as Robinhood's top stock. Here's what replaced it.

  • ContextLogic Inc. (NASDAQ:WISH) and the Problems With Cheap User Acquisition

    ContextLogic Inc. (NASDAQ:WISH) has gained a lot of attention recently, and investors are split between thinking that the company has high potential based on gross margins and revenue, and those who are concerned that the bottom has yet to be reached. In this article we will look at the performance, predictions as well as take a look at expenses and see why the market might have such a divergent view on the company.

  • Vaxart, Inc.'s (NASDAQ:VXRT) Shift From Loss To Profit

    Vaxart, Inc. ( NASDAQ:VXRT ) is possibly approaching a major achievement in its business, so we would like to shine...

  • 8 Companies Keep Making Much More Money Than Anyone Imagined

    S&P 500 profits are gushing in faster than expected. But some are making a habit out of blowing away profit expectations.

  • Why Sundial Growers, Hexo, and OrganiGram Stocks Jumped Today

    There's been some good news in the Canadian cannabis sector recently, but it hasn't been reflected in several of the stocks. Shares of three Canadian growers are rebounding some today, however. The stocks of Hexo (NYSE: HEXO) and OrganiGram Holdings (NASDAQ: OGI) were up 9.3% and 7.3%, respectively, as of 2:05 p.m. EDT.

  • These 2 Stocks Just Soared After Hours Monday

    Enthusiasm about the potential success of COVID-19 vaccination efforts and economic strength helped market participants lift major market indexes substantially. The Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) all were higher, with the Nasdaq finishing at a record and the S&P falling short by just a fraction of a point. Palo Alto Networks (NYSE: PANW) and Cara Therapeutics (NASDAQ: CARA) were both up by double-digit percentages late Monday, and below, we'll go into the details.

  • Morgan Stanley’s Slimmon Says Buy Reopening Before Too Late

    (Bloomberg) -- When clients call Andrew Slimmon for advice on how to position their portfolios given the rapid spread of the delta variant, he tells them in no uncertain terms: Prepare for an economic recovery, and soon. Slimmon, who oversees about $7.5 billion at Morgan Stanley Investment Management, says it’s not unusual to see economic hiccups this time of year. Going forward, “people will turn a little bit more optimistic,” which bodes well for equities that have sold off due to Covid-relate

  • Why Wall Street Thinks BioNTech Stock Could Sink 25%

    BioNTech (NASDAQ: BNTX) might not be the best-known of the leading COVID-19 vaccine makers. The company has been largely overshadowed by its big partner Pfizer and by Moderna, at least in the U.S. However, BioNTech has been the biggest winner in the group so far this year with its shares skyrocketing more than 350%. Here's why Wall Street thinks BioNTech stock could sink 25% within the next 12 months.

  • Semiconductors ‘under appreciated’, good long-term investment: expert

    Yahoo Finance’s Julie Hyman and Brian Sozzi break down today’s market action and outlook with Francisco Bido, F/M Integrated Alpha Investments Senior Vice President and Portfolio Manager.

  • Medtronic Reports First Quarter Fiscal 2022 Financial Results

    Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021.

  • 2 Powerful Warren Buffett Dividend Stocks You Can Buy Right Now

    Quick, can you name a famous investor who earns billions of dollars in dividends every year from publicly traded companies? If you said Warren Buffett, you've identified one star stock picker at the top of the list. Buffett and his investment vehicle Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) are huge on dividend stocks.

  • 10 Best Stocks to Invest In According to Chinese Billionaire Lei Zhang

    In this article, we will discuss 10 best stocks to invest in according to Chinese billionaire Lei Zhang based on Q1 holdings of the fund. If you want to skip our detailed analysis of Zhang’s history, investment philosophy, and hedge fund performance, go directly to 5 Best Stocks to Invest In According to Chinese Billionaire Lei […]